X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA PFIZER SHASUN PHARMA/
PFIZER
 
P/E (TTM) x 123.9 36.4 340.1% View Chart
P/BV x 8.5 5.4 159.2% View Chart
Dividend Yield % 0.2 0.6 36.6%  

Financials

 SHASUN PHARMA   PFIZER
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
PFIZER
Mar-18
SHASUN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs942,365 4.0%   
Low Rs461,625 2.8%   
Sales per share (Unadj.) Rs214.2430.3 49.8%  
Earnings per share (Unadj.) Rs5.378.7 6.8%  
Cash flow per share (Unadj.) Rs15.893.2 17.0%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %1.41.0 142.7%  
Book value per share (Unadj.) Rs53.3586.5 9.1%  
Shares outstanding (eoy) m56.6245.75 123.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.6 7.0%   
Avg P/E ratio x13.125.3 51.7%  
P/CF ratio (eoy) x4.421.4 20.6%  
Price / Book Value ratio x1.33.4 38.5%  
Dividend payout %18.725.4 73.7%   
Avg Mkt Cap Rs m3,95891,271 4.3%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m2,1643,143 68.8%   
Avg. sales/employee Rs ThNM7,484.8-  
Avg. wages/employee Rs ThNM1,195.0-  
Avg. net profit/employee Rs ThNM1,369.1-  
INCOME DATA
Net Sales Rs m12,12719,685 61.6%  
Other income Rs m2291,143 20.1%   
Total revenues Rs m12,35620,828 59.3%   
Gross profit Rs m1,0095,003 20.2%  
Depreciation Rs m594663 89.6%   
Interest Rs m4154 9,883.3%   
Profit before tax Rs m2305,479 4.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,878 -3.9%   
Profit after tax Rs m3023,601 8.4%  
Gross profit margin %8.325.4 32.7%  
Effective tax rate %-31.734.3 -92.3%   
Net profit margin %2.518.3 13.6%  
BALANCE SHEET DATA
Current assets Rs m6,88424,167 28.5%   
Current liabilities Rs m8,4569,544 88.6%   
Net working cap to sales %-13.074.3 -17.4%  
Current ratio x0.82.5 32.2%  
Inventory Days Days6255 111.9%  
Debtors Days Days10829 374.7%  
Net fixed assets Rs m4,9709,514 52.2%   
Share capital Rs m113458 24.8%   
"Free" reserves Rs m2,87526,375 10.9%   
Net worth Rs m3,02026,832 11.3%   
Long term debt Rs m1,81725 7,269.6%   
Total assets Rs m13,34736,900 36.2%  
Interest coverage x1.61,305.5 0.1%   
Debt to equity ratio x0.60 64,584.4%  
Sales to assets ratio x0.90.5 170.3%   
Return on assets %5.49.8 55.0%  
Return on equity %10.013.4 74.5%  
Return on capital %13.320.4 65.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84322 26,083.0%   
Fx outflow Rs m2,1731,489 146.0%   
Net fx Rs m3,669-1,466 -250.3%   
CASH FLOW
From Operations Rs m3983,318 12.0%  
From Investments Rs m-1,635-2,383 68.6%  
From Financial Activity Rs m1,309-1,104 -118.6%  
Net Cashflow Rs m71-169 -42.3%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 3.6 7.5 48.0%  
FIIs % 17.6 4.9 359.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 23.7 167.1%  
Shareholders   20,750 85,207 24.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare SHASUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY18); Net Profit Up 53.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, PFIZER has posted a net profit of Rs 1 bn (up 53.6% YoY). Sales on the other hand came in at Rs 5 bn (up 14.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS